RT Journal Article
SR Electronic
T1 Cervical and systemic innate immunity predictors of HIV risk linked to genital herpes acquisition and time from HSV-2 seroconversion
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.13.22270917
DO 10.1101/2022.02.13.22270917
A1 Y. Govender
A1 C Morrison
A1 P Chen
A1 X Gao
A1 H. Yamamoto
A1 T. Chipato
A1 S. Anderson
A1 R. Barbieri
A1 R. Salata
A1 G. F. Doncel
A1 R. N. Fichorova
YR 2022
UL http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270917.abstract
AB Objectives To examine innate immunity predictors of HIV-1 acquisition as biomarkers of HSV-2 risk and biological basis for epidemiologically established HIV-1 predisposition in HSV-2 infected women.Methods We analyzed longitudinal samples from HIV-1 negative visits of 1019 women before and after HSV-2 acquisition. We measured cervical and serum biomarkers of inflammation and immune activation previously linked to HIV-1 risk. Protein levels were Box–Cox transformed and odds ratios for HSV-2 acquisition were calculated based on top quartile or below/above median levels for all HSV-2 negative visits. Bivariate analysis determined the likelihood of HSV-2 acquisition by biomarker levels preceding infection. Linear mixed-effects models evaluated if biomarkers differed by HSV-2 status defined as negative, incident, or established infections with an established infection cut-off starting at 6 months.Results In the cervical compartment, two biomarkers of HIV-1 risk (low SLPI and high BD-2) also predicted HSV-2 acquisition. In addition, HSV-2 acquisition was associated with IL-1β, IL-6, IL-8, MIP-3α, ICAM-1 and VEGF when below median levels. Systemic immunity predictors of HSV-2 acquisition were high sCD14 and IL-6, with highest odds when concomitantly increased (OR=2.23, 1.49-3.35). Concomitant systemic and mucosal predictors of HSV-2 acquisition risk included: 1) serum top quartile sCD14 with cervical low SLPI, VEGF and ICAM-1, or high BD-2; serum high IL-6 with cervical low VEGF and ICAM-1, SLPI, IL-1β and IL-6, and 3) serum low CRP with cervical high BD-2. Most cervical biomarkers were decreased after HSV-2 acquisition compared to the HSV-2 negative visits, with incident infections associated with a larger number of suppressed cervical biomarkers and lower serum IL-6 levels compared to established infections.Conclusions A combination of systemic immunoinflammatory and cervical immunosuppressed states predicts HSV-2 acquisition. A persistently suppressed innate immunity during incident infection may add to the increased HIV-1 susceptibility.Key MessagesA combination of altered systemic and cervical immunity precedes and predicts risk of HSV-2 acquisition.Factors causing cervical mucosal imbalance (low SLPI and high BD-2) may predispose to both HIV-1 and HSV-2 acquisitionIn comparison to non-infected, HSV-2 infected women show suppressed cervical innate immunityCompared to women with established HSV-2 infection, those with incident infections within 6 months from seroconversion are more immunosuppressed both at the mucosal and peripheral level, adding to the biology of HIV predisposition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01 HD077888 and R01 HD099091.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Partners Human Research Committee/Brigham and Women's HospitalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author.